ALBERT LABS INTL. CORP.

Research ALBERT LABS INTL. CORP. (VB50) on Bullrun: market cap EUR 372.07K. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 372.07K.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2022CAD 0-CAD 7.06M-CAD 1.50Mn/a-0.13CAD 79.12Kn/a-CAD 365.32K
FY2021CAD 0-CAD 1.88M-CAD 1.05Mn/a-0.03CAD 76.70Kn/a-CAD 502.53K

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25EUR 372.07Kn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About ALBERT LABS INTL. CORP.

Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is ALBERT LABS INTL. CORP.'s market cap?

ALBERT LABS INTL. CORP.'s market capitalization is EUR 372.07K.

What does ALBERT LABS INTL. CORP. do?

Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.